Predictive Value of Embryonic Testing

Patients participating in the study will undergo a routine in vitro fertilization cycle. Trophectoderm biopsy will be performed on all blastocysts however biopsy samples will not be analyzed till the clinical outcome has been determined. The single, morphologically best embryo available will be selected for transfer. All clinical and laboratory care is identical to that of which subjects would receive if they were not participating in the study. This includes all pretreatment screening, in-cycle treatment, embryology procedures, single embryo transfer, pregnancy testing, and pregnancy follow-up (if pregnancy occurs).

Inclusion criteria

• Couples electing embryonic aneuploidy screening (PGS)
• Couples electing single embryo transfer

Exclusion criteria

• Any prior failed IVF cycle
• Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid
• Diagnosis of chronic endometritis
• Maximum day 3 FSH level of 12 or higher
• Anti-mullerian hormone level less than 0.5 g/mL, tested within previous year
• Total basal antral follicle count less than 8 follicles
• Male partner with <100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)
• BMI <18.5 or > 35
• Personal history of recurrent pregnancy loss (two or more pregnancy losses)
• Use of oocyte donation
• Use of gestational carrier
• Medical condition predisposing patient to high risk pregnancy
• Use of surgical procedures to obtain sperm
• Presence of hydrosalpinges that communicate with endometrial cavity
• Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation
• Single gene disorder or chromosomal rearrangement requiring a more detailed embryonic genetic analysis